Litwin IBD Pioneers
Supports early-stage, clinically relevant research to advance diagnosis, treatment, and understanding of Crohn’s disease and ulcerative colitis.
Funder: Crohn's and Colitis Foundation
Due Dates: March 2, 2026 (Year Two Renewal) | May 5, 2026 (LOI, Fall cycle) | June 2, 2026 (Pre-Application) | July 20, 2026 (Full Proposal, Fall) | November 16, 2026 (LOI, Spring cycle) | February 11, 2027 (Full Proposal, Spring) | July 23, 2027 (Full Proposal by invitation)
Funding Amounts: Up to $130,000/year (clinical studies) or $110,000/year (lab-based); max 2 years; total up to $260,000 including 10% indirect costs.
Summary: Supports innovative, clinically relevant research projects aimed at advancing the diagnosis, treatment, and understanding of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis.
Key Information: Open to investigators worldwide at non-profit institutions; requires faculty appointment for PI; two-stage application (LOI/Pre-Application then Full Proposal).
Description
This program supports early-stage, high-impact clinical and translational research in inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. The goal is to fund innovative pilot projects that have strong potential for near-term patient impact, whether through new diagnostics, therapeutics, or clinically relevant discoveries. The initiative welcomes proposals from established IBD researchers as well as investigators new to the field, including those from outside the United States.
Projects must address unmet needs in IBD, align with the Foundation's research priorities, and demonstrate potential for translation to patient care. Both clinical and laboratory-based studies are eligible, though the program prioritizes work with clear clinical relevance.
